back

Acute Lymphoblastic Leukemia Clinical Trials in Georgia

Cancer Type = Acute Lymphoblastic Leukemia

Cancer Type = Acute Lymphoblastic Leukemia

NCI ID Cancer Type Trial Name
There are currently 7 active Acute Lymphoblastic Leukemia clinical trials in Georgia.
NCI ID Cancer Type Trial Name
1.
A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (NSC# 102816) to Chemotherapy in Infants with Acute Lymphoblastic Leukemia (ALL) and KMT2A(MLL) Gene Rearrangement
Cancer Type
Acute Lymphoblastic Leukemia
NCI ID
NCT02828358
Protocol IDs
AALL15P1
NCI-2016-00973
Treatment Sites (2)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
Curtis and Elizabeth Anderson Cancer Institute at Memorial University Medical Center
Savannah
Joni N. Shortt, RN, BSN, CCRC
912-350-8913
2.
A Phase 1 Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
Cancer Type
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Leukemia, Lymphoma, Neuroblastoma
NCI ID
NCT03236857
Protocol IDs
M13-833
NCI-2017-02027
2017-000439-14
3.
A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia
Cancer Type
Acute Lymphoblastic Leukemia
NCI ID
NCT02723994
Protocol IDs
INCB 18424-269
NCI-2016-01687
AALL1521
4.
A Phase I Trial of Temsirolimus (CCI-779, Pfizer, Inc.) in Combination With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma
Cancer Type
Acute Lymphoblastic Leukemia, Non-Hodgkin Lymphoma
NCI ID
NCT01614197
Protocol IDs
T2014-001
NCI-2012-01493
T2008-004
5.
A Pilot Study of Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults With Relapse of Acute Lymphoblastic Leukemia
Cancer Type
Acute Lymphoblastic Leukemia, Leukemia, Lymphoma
NCI ID
NCT02879643
Protocol IDs
T2012-002
NCI-2016-01398
6.
Matched Targeted Therapy (MTT) Recommendation for Patients with Recurrent, Refractory, or High Risk Leukemias
Cancer Type
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Leukemia, Lymphoma, Myelodysplastic Syndromes (MDS)
NCI ID
NCT02670525
Protocol IDs
15-384
NCI-2016-00336
7.
Phase 1b/2 Study of Carfilzomib in Combination With Dexamethasone, Mitoxantrone, PEG-asparaginase, and Vincristine (UK R3 Induction Backbone) in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia
Cancer Type
Acute Lymphoblastic Leukemia
NCI ID
NCT02303821
Protocol IDs
CFZ008
NCI-2014-02601
2014-001633-84
About Us Research Resources & Education Screening & Genetics Clinical Trials & Providers Cancer Navigators Survivorship Media, News & Events Contact Us Donate Take Our Survey Link to Us

Research

Screening & Genetics

Clinical Trials & Providers

Survivorship

About Us

Resources & Education

Media, News & Events

More Helpful Links

Georgia CORE

 

Hearts and Minds Dedicated to Improving Cancer Care

Georgia CORE is a public-private partnership that creates collaboration among the state’s cancer organizations and institutions to connect more Georgians to quality, personalized cancer care. We welcome you to this one-of-a-kind online information center for all things related to cancer and survivorship care in Georgia.